- lot L1P1-6100/Expiration date June 25, 2016
- lot L1P2-6000/Expiration date September 16, 2016
Nano Well-being Health Inc. has issued a voluntary recall of Super Arthgold, 500 mg capsules. Super Arthgold is a dietary supplement used for joint pain and arthritis. FDA lab analysis has found the product to contain chlorzoxazone, diclofenac and indomethacin, making it an unapproved new drug. Use of this product may result in fatal adverse events in patients with underlying illnesses, including known allergy to the hidden ingredients, cardiac, gastrointestinal, hepatic, and renal conditions as well as patients who recently undergone cardiac bypass graft surgery. Consumers would be unaware that the product contains Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (and other ingredients) and may inadvertently overdose by taking another NSAID concurrently, thus increasing the risk for NSAID associated adverse events, which include but are not limited to, myocardial infarction, stroke, congestive heart failure, renal toxicity, and bleeding, ulceration, or perforation of the stomach or intestines. Affected lots include:
Earlier this week the FDA approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA), a form of arthritis that affects some people with psoriasis. The main symptoms of PsA are joint pain, stiffness and swelling. Otezla is an inhibitor of phosphodieasterase-4 (PDE-4). In clinical trials, patients who took Otezla showing improvement in symptoms of PsA. The most common side effects were diarrhea, nausea, and headache. Treatment with Otezla was also associated with an increase in report of depression compared to placebo.
 FDA News Release "FDA approves Otezla to treat psoriatic arthritis" (March 21, 2014).